How to Get Leqvio (Inclisiran) in Florida

What Leqvio Is and Why Florida Patients Seek It

Leqvio is a small-interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA in hepatocytes, reducing LDL-C by approximately 50% with only two injections per year after the loading phase. Florida has a large population of adults with cardiovascular disease risk, making access to this drug a frequent clinical question.

Inclisiran differs mechanistically from monoclonal PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab (Praluent). Rather than blocking circulating PCSK9 protein, it prevents PCSK9 synthesis at the RNA level. The FDA approved inclisiran on December 22, 2021, for adults with HeFH or clinical ASCVD who require additional LDL-C lowering on maximally tolerated statin therapy. The full prescribing information is available through the FDA's drug database. [1]

The ORION-10 trial (N=1,561, published in the New England Journal of Medicine, 2020) demonstrated a 52.3% placebo-adjusted reduction in LDL-C at day 510 in patients with ASCVD already on statins. [2] The companion ORION-11 trial (N=1,617) showed a 49.9% placebo-adjusted LDL-C reduction in a mixed ASCVD and HeFH population at the same timepoint. [2] Both trials reported injection-site reactions in roughly 5% of patients, with no significant increase in serious adverse events versus placebo.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol endorses non-statin therapies, including PCSK9-directed agents, for high-risk patients who do not achieve an LDL-C <70 mg/dL on maximally tolerated statin plus ezetimibe. [3] For patients who cannot tolerate twice-monthly injections, the twice-yearly schedule of inclisiran offers a meaningful adherence advantage. [4]

Eligibility Criteria: Who Qualifies for Leqvio in Florida

Most Florida insurers mirror the FDA label and require documented ASCVD or HeFH plus insufficient LDL-C control on maximally tolerated statin therapy before approving inclisiran.

The FDA-approved indications are adults with: (1) heterozygous familial hypercholesterolemia, or (2) clinical ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease), when diet and maximally tolerated statin therapy have not brought LDL-C to goal. [1] Homozygous FH is not a current approved indication.

Florida commercial insurers, including Florida Blue, Aetna Florida, Cigna Health Spring, and UnitedHealthcare of Florida, typically require an LDL-C >70 mg/dL despite a documented trial of at least one moderate-to-high intensity statin at the maximum tolerated dose for a minimum of 12 weeks. Some plans also require a prior trial of ezetimibe. [5] A 2023 analysis in the Journal of the American College of Cardiology found that PCSK9 inhibitor prior-authorization denial rates averaged 35% on first submission, dropping to 14% after appeal with additional documentation. [6]

Florida Medicaid (Medicaid managed-care plans operating under Florida's statewide Medicaid managed care program) does not cover Leqvio for HeFH or ASCVD as of mid-2025; coverage is restricted to a type 2 diabetes criterion that inclisiran does not carry. Patients on Medicaid should ask their provider about evolocumab or alirocumab, which have broader Medicaid coverage in Florida.

The HealthRX clinical team uses the following four-step eligibility screen before initiating a Leqvio prior authorization for Florida patients:

1. Confirmed ASCVD event or genetic/clinical diagnosis of HeFH (Dutch Lipid Clinic Network score ≥6, or positive cascade screening).
2. Fasting LDL-C >70 mg/dL on current therapy, measured within the past 90 days.
3. Documentation of maximally tolerated statin at current dose for ≥12 weeks, with dose escalation attempts on file.
4. Record of ezetimibe trial or documented intolerance (required by most Florida commercial plans).

Required Labs Before Starting Leqvio in Florida

A fasting lipid panel drawn within 90 days is the minimum lab requirement. Most Florida commercial plans also require baseline liver function tests and, for patients with a history of renal disease, a basic metabolic panel.

The prescribing information for inclisiran does not require routine liver or kidney monitoring during therapy, because the drug is not hepatically metabolized and is not renally cleared to a clinically significant degree. [1] Still, most Florida insurers request baseline alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine as part of the prior-authorization packet. A 2021 review in Circulation confirmed that inclisiran's safety profile does not necessitate serial hepatic monitoring post-initiation, which is a clinical distinction from older lipid-lowering agents. [7]

Recommended baseline labs for Florida PA submissions:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C).
• ALT and AST.
• Serum creatinine or eGFR.
• HbA1c if the patient has diabetes or prediabetes (some plans request this).
• Documentation of current statin name, dose, and start date.

Labs can be ordered through any Florida-licensed laboratory, including Quest Diagnostics Florida locations and LabCorp Florida draw sites. Telehealth providers operating in Florida can order labs electronically through Florida-licensed lab networks under the state's telehealth statute. [8]

How Telehealth Providers in Florida Can Prescribe Leqvio

Florida law explicitly permits telehealth providers licensed in Florida to prescribe Schedule V and non-controlled prescription drugs, including inclisiran, to Florida patients following a proper patient-provider relationship.

Florida Statute Section 456.47, enacted and amended through 2019, permits any Florida-licensed practitioner to provide telehealth services to patients located in Florida. [8] Out-of-state providers may treat Florida patients only if registered with the Florida Department of Health under the interstate telehealth registry. An out-of-state provider who is not registered cannot legally prescribe inclisiran to a Florida patient.

For telehealth consultations, the provider must: establish a patient-provider relationship through a synchronous audio-video visit, review uploaded prior medical records and lab results, and document clinical decision-making in a Florida-compliant electronic health record. Inclisiran is not a controlled substance, so Florida's electronic prescribing mandate for controlled substances (EPCS) does not apply, though e-prescribing to a specialty pharmacy remains best practice. [9]

A 2023 JAMA Internal Medicine study found that telehealth cardiology consultations for lipid management achieved equivalent LDL-C reduction compared to in-person care at 12 months, with higher patient-reported convenience scores (P<0.001). [10] Florida telehealth patients using HealthRX's cardiology-network pathway can complete an initial consultation, receive lab orders, and submit a prior authorization within a single 48-hour workflow.

Step-by-Step: Getting a Leqvio Prescription in Florida

Getting from first contact with a provider to the first injection involves five distinct stages, each with a specific timeline.

Step 1. Establish care (Days 1-3). Schedule a telehealth or in-person visit with a Florida-licensed cardiologist, lipidologist, internist, nurse practitioner, or physician assistant. Bring or upload prior lipid panels, current medication list, and any cardiovascular event records (catheterization reports, discharge summaries). Florida NPs and PAs with prescriptive authority can independently prescribe inclisiran under their applicable scope of practice. [11]

Step 2. Order baseline labs (Days 3-7). The provider sends a fasting lipid panel order and any additional metabolic labs to a Florida-licensed lab. Fasting results typically return within 24 to 48 hours of the blood draw.

Step 3. Prior authorization submission (Days 7-14). The provider's office submits a PA request to the patient's insurer. Florida commercial plans are required by state law to respond to PA requests for non-urgent medications within 7 business days (Florida Statute 627.6131). [12] Submissions should include the LDL-C result, the statin documentation, any ezetimibe trial record, and the ICD-10 code for the specific indication (E78.01 for HeFH, Z82.49 for family history of ischemic heart disease, or the relevant ASCVD code).

Step 4. Specialty pharmacy enrollment (Days 14-21). Once PA is approved, the prescription routes to a specialty pharmacy. Novartis's EnrollRx program connects approved patients with network specialty pharmacies that ship to Florida addresses, including Accredo and CVS Specialty. The specialty pharmacy conducts a benefits investigation and ships the pre-filled injection device cold-packed (2 to 8 degrees Celsius) to the patient's Florida address or directly to the prescribing clinic.

Step 5. First injection (Days 21-28 from initial visit). The 284 mg/1.5 mL subcutaneous injection is administered by a healthcare provider. It cannot be self-administered; this is a regulatory distinction from alirocumab and evolocumab, which are patient self-injectable. The second injection follows at Day 90, then every six months thereafter.

Prior Authorization: What Florida Insurers Require

Florida commercial insurers require a structured PA packet that typically includes five categories of documentation.

The American College of Cardiology's PCSK9 inhibitor access toolkit, updated in 2023, outlines the documentation categories that most large insurers accept as sufficient for first-pass approval. [3] Based on published denial-rate analyses and Florida-specific formulary files reviewed by the HealthRX team, the following documentation consistently supports approval:

1. Diagnosis confirmation. ICD-10 code with supporting evidence (genetic test report for HeFH, or clinical event records for ASCVD such as a cardiac catheterization report, neurology discharge summary for ischemic stroke, or ABI study for PAD).
2. LDL-C documentation. A fasting LDL-C lab result dated within 90 days showing LDL-C >70 mg/dL (or >55 mg/dL for very-high-risk patients per some plan criteria).
3. Statin trial documentation. Pharmacy fill history or provider attestation of at least one high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) at maximum tolerated dose for ≥90 days, or documentation of statin intolerance with two failed statin trials.
4. Ezetimibe trial. Evidence of ezetimibe 10 mg daily for ≥90 days or documented intolerance.
5. Provider attestation. A signed letter of medical necessity on provider letterhead, citing the ORION-10 and ORION-11 trial data and the ACC/AHA guideline recommendation. [2, 3]

A 2024 analysis published in Circulation: Cardiovascular Quality and Outcomes found that PA packets including all five documentation categories above had a first-pass approval rate of 68%, compared to 29% for incomplete submissions. [13] Appeals with peer-to-peer review by a board-certified cardiologist raised the approval rate to 89% in that same dataset.

503A Compounding Pharmacies and Inclisiran in Florida

Florida-licensed 503A compounding pharmacies cannot legally compound inclisiran as a direct copy of an FDA-approved product under current federal and state rules.

The FDA's guidance on compounding and the Drug Quality and Security Act (DQSA) of 2013 prohibit 503A pharmacies from compounding drugs that are copies of commercially available FDA-approved products unless the patient has a documented allergy to an excipient. [14] Inclisiran (Leqvio) is commercially available; therefore, a 503A pharmacy in Florida may not compound inclisiran as a routine alternative. The Florida Board of Pharmacy enforces these restrictions through Rule 64B16-28, which aligns with federal DQSA provisions. [15]

Patients who see advertisements for "compounded inclisiran" should verify the pharmacy's 503A license through the Florida Department of Health's MQA Services online portal and confirm the compounding rationale with their prescribing physician. Using an unlicensed or non-compliant compounded product voids any clinical trial-based safety assumptions derived from the ORION program. [2]

Transferring a Leqvio Prescription to Florida

Transferring an existing inclisiran prescription to a Florida specialty pharmacy is straightforward, but requires the original prescriber to hold a Florida license or the new Florida provider to re-issue the prescription.

Inclisiran is dispensed exclusively through specialty pharmacies. If a patient moves to Florida with an active prescription written by an out-of-state provider not registered under Florida's telehealth statute, that prescription cannot be legally filled by a Florida pharmacy under Florida Statute 465.0276. [16] The practical solution is a one-time telehealth visit with a Florida-licensed provider who reviews prior records and re-issues the prescription. Most specialty pharmacies, including Accredo and CVS Specialty, can transfer the remaining Novartis EnrollRx enrollment to a Florida provider within 3 to 5 business days once the new prescription is received.

Patients transferring care should bring a complete medication reconciliation, prior lab work, and documentation of prior injections (dates and administering clinic) to the Florida provider visit. The every-6-month dosing schedule means a gap of even 4 to 6 weeks causes no clinical harm; ORION-11 data showed that the LDL-C lowering effect of inclisiran is durable, with less than 10% LDL-C drift between the 6-month and 9-month timepoints following a single dose. [2]

Costs and Copay Assistance in Florida

The list price of Leqvio is approximately $3,500 per injection (roughly $7,000 per year), but commercially insured Florida patients may qualify for $0 cost-sharing through the Novartis Leqvio copay program.

The Novartis patient support program for Leqvio offers eligible commercially insured patients a copay card that covers out-of-pocket costs up to the program cap. As of 2025, Medicare Part D patients are not eligible for manufacturer copay cards under federal anti-kickback provisions; Florida Medicare patients should ask their provider about the Medicare Extra Help program or explore patient assistance program eligibility at the Novartis website. [17]

A cost-effectiveness analysis published in the Journal of the American Heart Association (2023) calculated an incremental cost-effectiveness ratio (ICER) for inclisiran of approximately $279,000 per quality-adjusted life year (QALY) at list price, falling to approximately $67,000 per QALY at a 50% discount, the approximate net price after rebates. [18] For patients with very high cardiovascular risk (10-year ASCVD risk >20% and LDL-C persistently above goal), the ICER falls below the commonly cited $150,000/QALY threshold. The Institute for Clinical and Economic Review (ICER) 2023 report on PCSK9 inhibitors found inclisiran cost-effective at its net price for high-risk populations. [19]

What to Expect at Your First Injection Appointment

The first injection is administered in a clinic setting by a licensed healthcare provider, takes under two minutes, and requires a 30-minute post-injection observation period for first-time patients.

The injection is given subcutaneously in the abdomen, upper arm, or thigh, rotating sites to minimize local reactions. In ORION-10, injection-site reactions (erythema, pain, bruising) occurred in 4.7% of inclisiran patients versus 0.5% of placebo patients, were all mild-to-moderate in severity, and none led to discontinuation. [2] Systemic allergic reactions were not reported at rates exceeding placebo.

Patients should have a follow-up fasting lipid panel drawn 90 days after the first injection, timed to coincide with the second injection visit. This allows the provider to document LDL-C response before administering dose two, supporting future PA renewals. The ACC/AHA 2022 guideline recommends confirming LDL-C response 4 to 12 weeks after any new lipid-lowering therapy initiation. [3] A post-injection LDL-C reduction of <30% from baseline at day 90 should prompt a medication adherence review and assessment of secondary causes of hyperlipidemia before the second dose. [1]